Laurent Hocqueloux

Laurent Hocqueloux

Auto-generated profile, based on publicly available information

Laurent Hocqueloux

Infectious Disease Department, Orléans University Hospital, Orléans, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
DPDelphine Planas
Delphine Planas
DVDavid Veyer
David Veyer
ABArtem Baidaliuk
Artem Baidaliuk
ISIsabelle Staropoli
Isabelle Staropoli
FGFlorence Guivel-Benhassine
Florence Guivel-Benhassine
OSOlivier Schwartz
Olivier Schwartz

23 March 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TBTimothée Bruel
Timothée Bruel
JHJérôme Hadjadj
Jérôme Hadjadj
PMPiet Maes
Piet Maes
DPDelphine Planas
Delphine Planas
ASAymeric Seve
Aymeric Seve
OSOlivier Schwartz
Olivier Schwartz

20 January 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
LHLaurent Hocqueloux
Laurent Hocqueloux
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
SJSophie Jacquot
Sophie Jacquot
TPThierry Prazuck
Thierry Prazuck
ELEric Legac
Eric Legac
CRChristine Rouzioux
Christine Rouzioux
To characterize viro-immunological outcomes following long-term combined antiretroviral therapy (cART) initiated during primary HIV infection (PHI) or chronic HIV infection (CHI) and to identify factors predictive of optimal viro-immunological responder (OVIR) status. This was a prospective, single-centre cohort study of HIV-1-infected patients on effective cART. Total cell-associated HIV DNA levels and T cell counts before and during treatment were used to identify factors predictive of OVIR status {i.e. low HIV DNA level [<2.3 log10 copies/106 peripheral blood mononuclear cells (PBMCs)], together with normalization of the absolute/relative CD4+ T cell counts and CD4+/CD8+ ratio}. A total of 307 patients were enrolled, of whom 35 started cART during PHI (<4 months post-infection) and 272 during CHI. HIV DNA decay was modelled with a non-linear mixed-effects model that showed two phases of HIV DNA decay, both of which were significantly more pronounced in the PHI group. At the end of follow-up, after a median of 4 years of viral suppression (<50 copies/mL), HIV DNA levels were lower in the PHI group than in the CHI group (median = 2.15 versus 2.84 log10 copies/106 PBMCs; P< 0.0001). Immune reconstitution was more rapid and sustained in the PHI group (median = 883 versus 619 CD4+ cells/mm3; 41% versus 31% CD4+; CD4+/CD8+ 1.31 versus 0.77; all P< 0.0001). Finally, OVIR status was obtained in 19/35 (54%) and 7/272 (3%) patients in the PHI and CHI groups (P< 0.0001), respectively. In a logistic regression analysis, cART initiation during PHI (OR = 16, 95% CI = 3.5–72.3) and HIV DNA level <3.3 log10 before treatment (OR = 4.8, 95% CI = 1.2–19.3) were independently predictive of OVIR status. Initiating cART during PHI represents a major opportunity to reduce HIV reservoirs and achieve optimal immune reconstitution.

14 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDelphine Planas
Delphine Planas
TBTimothée Bruel
Timothée Bruel
ISIsabelle Staropoli
Isabelle Staropoli
FGFlorence Guivel-Benhassine
Florence Guivel-Benhassine
FPFrançoise Porrot
Françoise Porrot
OSOlivier Schwartz
Olivier Schwartz
Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariant BQ.1.1 became predominant in many countries in December 2022. The subvariants carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lose antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remaine weakly active. BQ.1.1 is also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals are low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increases these titers, which remains about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increases more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitates their spread in immunized populations and raises concerns about the efficacy of most available mAbs.

19 June 2010 in AIDS
Verified
Journal Article
Closed access
LHLaurent Hocqueloux
Laurent Hocqueloux
TPThierry Prazuck
Thierry Prazuck
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
ALAlain Lafeuillade
Alain Lafeuillade
BCBernard Cardon
Bernard Cardon
CRChristine Rouzioux
Christine Rouzioux
Five out of 32 patients who received very early and prolonged antiretroviral therapy displayed an unusual, sustained immunovirological control after treatment discontinuation (mean duration: 77 months). These ‘post-treatment controllers’ did not have the genetic characteristics of spontaneous ‘elite’ controllers, although they shared very low and stable level of viral reservoir. Treatment may have dramatically decreased this reservoir and preserved potent HIV-specific immunologic responses, inducing a new balance between the virus and the host's immune system in these patients.

15 October 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
TMThomas Maho
Thomas Maho
RBRaphaelle Binois
Raphaelle Binois
FBFabienne Brulé-Morabito
Fabienne Brulé-Morabito
MDMaryvonne Demasure
Maryvonne Demasure
Claire DouatClaire Douat
Claire Douat
ERERIC ROBERT
ERIC ROBERT
This work is a contribution to the development and implementation of non-thermal plasma technology for decontamination in the perspective of nosocomial and chronic wound innovative therapies. Multi jets devices based on Plasma Gun® technology in static and scanning operation modes and bacterial lawns inoculated with resistant and non-resistant bacterial strains were designed and used. A pilot toxicity study exploring plasma treatment of wound bearing patients, performed with a low voltage plasma applicator, is documented as a first step for the translation of in vitro experiments to clinical care. Bacterial inactivation was demonstrated for Staphylococcus aureus, Pseudomonas aeruginosa and drug resistant S. aureus, P. aeruginosa and Escherichia Coli strains collected from patient wounds at Orleans (France) hospital. A few square centimeter large contaminated samples were inactivated following a single plasma exposure as short as one minute. Samples inoculated with a single but also a mix of three resistant pathogens were successfully inactivated not only right after their contamination but for mature lawns as well. Similar bactericidal action was demonstrated for antibiotic-resistant and non-resistant P. aeruginosa. The time exposure dependent increase of the inhibition spots, following multi jets exposure, is discussed as either the accumulation of reactive species or the likely combinatory action of both the reactive species and transient electric field delivery on inoculated samples.